Circulating transforming growth factor-β in marfan syndrome

Circulation

Volumn 120, Issue 6, 2009, Pages 526-532

  Matt, Peter ^a,b,c   Schoenhoff, Florian ^a,b,c   Habashi, Jennifer ^a   Holm, Tammy ^a   Van Erp, Christel ^a   Loch, David ^a   Carlson, Olga D ^e   Griswold, Benjamin F ^e   Fu, Qin ^d   De Backer, Julie ^f   Loeys, Bart ^f   Huso, David L ^g   McDonnell, Nazli B ^e   Van Eyk, Jennifer E ^d   Dietz, Harry C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e NATIONAL INSTITUTE ON AGING   (United States)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aneurysm; Biomarkers; Losartan; Marfan syndrome; TGF beta

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRILLIN 1; LOSARTAN; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; ANGIOTENSIN RECEPTOR ANTAGONIST; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ANIMAL EXPERIMENT; AORTA ROOT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; ENZYME INHIBITION; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MARFAN SYNDROME; MOUSE; NONHUMAN; PATIENT INFORMATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; THERAPY EFFECT; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; AORTA; BLOOD; C57BL MOUSE; ECHOCARDIOGRAPHY; ECHOGRAPHY; GENETICS; HETEROZYGOTE; MIDDLE AGED; MOUSE MUTANT;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; BIOLOGICAL MARKERS; ECHOCARDIOGRAPHY; FEMALE; HETEROZYGOTE; HUMANS; LOSARTAN; MALE; MARFAN SYNDROME; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MIDDLE AGED; PROGNOSIS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 69449090360     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.841981     Document Type: Article

References (22)

1. Judge DP, Dietz HC. Marfan's syndrome. Lancet. 2005;366:1965-1976.
2. Pearson GD, Devereux R, Loeys B, Maslen C, Milewicz D, Pyeritz R, Ramirez F, Rifkin D, Sakai L, Svensson L, Wessels A, Van Eyk J, Dietz HC. Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on research in Marfan syndrome and related disorders. Circulation. 2008;118:785-791.
3. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, Puffenberger EG, Hamosh A, Nanthakumar EJ, Curristin SM, Stetten G, Meyers DA, Francomano CA. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352:337-339.
4. Matt P, Habashi J, Carrel T, Cameron DE, Van Eyk JE, Dietz HC. Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan? J Thorac Cardiovasc Surg. 2008;135: 389-394.
5. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003;33: 407-411.
6. Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, Gabrielson KL, Hausladen JM, Mecham RP, Judge DP, Dietz HC. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest. 2004;114:1586-1592.
7. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117-121.
8. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med. 2007;13:204-210.
9. Judge DP, Biery NJ, Keene DR, Geubtner J, Myers L, Huso DL, Sakai LY, Dietz HC. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest. 2004; 114:172-181.
10. Lavoie P, Robitaille G, Agharazii M, Ledbetter S, Lebel M, Lariviere R. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J Hypertens. 2005;23: 1895-1903.
11. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC III. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med. 2008;358:2787-2795.
12. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463.
13. Cox DA, Maurer T. Transforming growth factor-beta. Clin Immunol Immunopathol. 1997;83:25-30.
14. Gleizes PE, Munger JS, Nunes I, Harpel JG, Mazzieri R, Noguera I, Rifkin DB. TGF-beta latency: biological significance and mechanisms of activation. Stem Cells. 1997;15:190-197.
15. Mangasser-Stephan K, Gressner AM. Molecular and functional aspects of latent transforming growth factor-beta binding protein: just a masking protein? Cell Tissue Res. 1999;297:363-370.
16. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, Sheppard D. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96:319-328.
17. Segura AM, Luna RE, Horiba K, Stetler-Stevenson WG, McAllister HA Jr, Willerson JT, Ferrans VJ. Immunohistochemistry of matrix metallo-proteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome. Circulation. 1998;98: II331-II337.
18. Burgio RG, Martini A, Cetta G, Zanaboni G, Vitellaro L, Danesino C. Asymmetric Marfan syndrome. Am J Med Genet. 1988;30:905-909.
19. Ahimastos AA, Aggarwal A, D'Orsa KM, Formosa MF, White AJ, Savarirayan R, Dart AM, Kingwell BA. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA. 2007;298:1539-1547.
20. Shigeyama J, Yasumura Y, Sakamoto A, Ishida Y, Fukutomi T, Itoh M, Miyatake K, Kitakaze M. Increased gene expression of collagen types I and III is inhibited by beta-receptor blockade in patients with dilated cardiomyopathy. Eur Heart J. 2005;26:2698-2705.
21. Chung AW, Yang HH, Radomski MW, van Breemen C. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in Marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res. 2008;102:e73-e85.
22. Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U, Schluter KD, Bohm M. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol. 2002;283:H1253-H1262.